Paper Details

  1. Home
  2. Paper Details

[A double-blind comparative study on the efficacy of S6472, cefaclor, in the treatment of bacterial bronchitis].

Author: AbeM, ItohC, KikuiriT, KuriharaY, MurakamiT, NishiharaH, OshimaS, ShimizuT, TakeuchiK, YokoyamaY

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

S6472 (long-acting cefaclor) was found to be equally effective in treating bacterial bronchitis as cefaclor, with similar safety profiles. It can be taken twice a day instead of three times a day.
Paper Details　
Original Abstract of the Article :
Clinical efficacy and safety of S6472 (long active cefaclor (CCL)) and CCL were compared by a double-blind study using 248 patients with bacterial bronchitis. Patients were orally administered with either 375 mg of S6472 2 times or 250 mg of CCL 3 times daily for 7 days, and the following results we...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3543432

データ提供：米国国立医学図書館（NLM）

S6472 vs. Cefaclor: A Duel in Bacterial Bronchitis Treatment

The world of antibiotics is a complex one, with new drugs constantly emerging. This research compares the efficacy and safety of two antibiotics, S6472 and cefaclor, in treating bacterial bronchitis. Researchers conducted a double-blind comparative study involving 248 patients, ensuring that both patients and doctors were unaware of the treatment received. This meticulous design helps to eliminate bias and provide reliable results.

A Tie in the Battle

The study concluded that S6472, taken twice daily, is equivalent to cefaclor in effectiveness on bacterial bronchitis. This is an important finding for doctors, who can now confidently choose either medication based on individual patient needs and preferences. Both antibiotics demonstrated similar clinical efficacy and bacteriological efficacy rates, with no significant difference in side effects. It’s like a tie in a fierce desert duel.

Antibiotics: A Powerful Tool, But Use with Caution

Antibiotics are powerful tools in the fight against bacterial infections, but they should be used with caution. Overuse of antibiotics can lead to antibiotic resistance, making infections more difficult to treat. It’s important to always follow your doctor’s instructions and only take antibiotics when prescribed.

Dr.Camel's Conclusion

This research provides valuable insights into the treatment of bacterial bronchitis. It's like finding a reliable guide through the challenging landscape of bacterial infections. S6472 and cefaclor offer doctors and patients valuable options, with both demonstrating effectiveness and safety.

Date :
  1. Date Completed 1987-03-24
  2. Date Revised 2016-11-16
Further Info :

Pubmed ID

3543432

DOI: Digital Object Identifier

3543432

Related Literature

Article Analysis
・Side Effects of cephalexin
SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.